EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Opinion
Video

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Presented by the Onc Brothers
Related Content